Toll Free: 1-888-928-9744

Applied Genetic Technologies Corporation - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Applied Genetic Technologies Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Applied Genetic Technologies Corporation - Product Pipeline Review - 2014', provides an overview of the Applied Genetic Technologies Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Applied Genetic Technologies Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Applied Genetic Technologies Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Applied Genetic Technologies Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Applied Genetic Technologies Corporation's pipeline products

Reasons to buy

- Evaluate Applied Genetic Technologies Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Applied Genetic Technologies Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Applied Genetic Technologies Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Applied Genetic Technologies Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Applied Genetic Technologies Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Applied Genetic Technologies Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Applied Genetic Technologies Corporation Snapshot 5
Applied Genetic Technologies Corporation Overview 5
Key Information 5
Key Facts 5
Applied Genetic Technologies Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
Applied Genetic Technologies Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Applied Genetic Technologies Corporation - Pipeline Products Glance 12
Applied Genetic Technologies Corporation - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Applied Genetic Technologies Corporation - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Applied Genetic Technologies Corporation - Drug Profiles 15
rAAV1-CB-hAAT 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
rAAV2-CB-hAAT 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
rAAV2-CB-hRPE65 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Gene Therapy for Achromatopsia 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Gene Therapy for Ophthalmology 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Gene Therapy for Respiratory Disorders 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for X-linked Retinoschisis 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Applied Genetic Technologies Corporation - Pipeline Analysis 24
Applied Genetic Technologies Corporation - Pipeline Products by Target 24
Applied Genetic Technologies Corporation - Pipeline Products by Route of Administration 25
Applied Genetic Technologies Corporation - Pipeline Products by Molecule Type 26
Applied Genetic Technologies Corporation - Pipeline Products by Mechanism of Action 27
Applied Genetic Technologies Corporation - Recent Pipeline Updates 28
Applied Genetic Technologies Corporation - Dormant Projects 29
Applied Genetic Technologies Corporation - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32
List of Tables
Applied Genetic Technologies Corporation, Key Information 5
Applied Genetic Technologies Corporation, Key Facts 5
Applied Genetic Technologies Corporation - Pipeline by Indication, 2014 7
Applied Genetic Technologies Corporation - Pipeline by Stage of Development, 2014 8
Applied Genetic Technologies Corporation - Monotherapy Products in Pipeline, 2014 9
Applied Genetic Technologies Corporation - Out-Licensed Products in Pipeline, 2014 10
Applied Genetic Technologies Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 11
Applied Genetic Technologies Corporation - Phase II, 2014 12
Applied Genetic Technologies Corporation - Phase I, 2014 13
Applied Genetic Technologies Corporation - Preclinical, 2014 14
Applied Genetic Technologies Corporation - Pipeline by Target, 2014 24
Applied Genetic Technologies Corporation - Pipeline by Route of Administration, 2014 25
Applied Genetic Technologies Corporation - Pipeline by Molecule Type, 2014 26
Applied Genetic Technologies Corporation - Pipeline Products by Mechanism of Action, 2014 27
Applied Genetic Technologies Corporation - Recent Pipeline Updates, 2014 28
Applied Genetic Technologies Corporation - Dormant Developmental Projects,2014 29 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify